Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 32 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 2 - Drugs In Development, 2022, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 2, 1, 13 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Mycosis Fungoides, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Huntington Disease, Lewy Body Dementia, Parkinson's Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Adenoid Cystic Carcinoma (ACC), Anal Cancer, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Frontotemporal Dementia (FTD), Gallbladder Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hemoglobinopathies, High-Grade Glioma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Liver Fibrosis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.
Furthermore, this report also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
• The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
• The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope